Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 juil. 2025 07h00 HE | Source: Bonus Biogroup

Bonus Biogroup Appoints Renowned Cell Therapy Leader, Professor Edwin M. Horwitz, MD, PhD, to its Advisory Board

HAIFA, Israel, July 14, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop...
20 févr. 2025 08h00 HE | Source: Bonus Biogroup

Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress

The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS) MesenCure's market potential...
22 août 2021 04h20 HE | Source: Bonus BioGroup

Bonus BioGroup Receives Approval to Expand Phase-II Clinical Trials for its COVID-19 Treatment to Medical Centers Across Israel

TEL AVIV, ISRAEL, Aug. 22, 2021 (GLOBE NEWSWIRE) -- Bonus BioGroup LTD or "the Company" (BONS.TA), an Israeli clinical-stage biotechnology company, has received official approval from the Israeli...